The FDA has approved Opdivo (nivolumab) from E.R. Squibb & Sons, L.L.C., a key asset for the manufacturer's oncology franchise that is poised to bolster market share within the expanding immuno-oncology sector.
The FDA has approved Opdivo (nivolumab) from E.R. Squibb & Sons, L.L.C., a key asset for the manufacturer's oncology franchise that is poised to bolster market share within the expanding immuno-oncology sector.